# Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Study · id `cardio:ct-nct01394952` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01394952](<https://clinicaltrials.gov/study/NCT01394952>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01394952

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9901 participants.

## Technical summary

Registry record NCT01394952. Randomized; double masking; primary purpose treatment. Start 2011-07-22 (actual); primary completion 2018-08-21 (actual). Results posted on 2019-10-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 9901 participants (enrolled count; ClinicalTrials.gov record NCT01394952, source copy `cardio:ctgov-nct01394952-2019-10-08`, retrieved 2026-10-26)
- Started: 2011-07-22 (actual) (ClinicalTrials.gov record NCT01394952, source copy `cardio:ctgov-nct01394952-2019-10-08`, retrieved 2026-10-26)
- Primary completion: 2018-08-21 (actual) (ClinicalTrials.gov record NCT01394952, source copy `cardio:ctgov-nct01394952-2019-10-08`, retrieved 2026-10-26)
- Completion: 2018-08-21 (actual) (ClinicalTrials.gov record NCT01394952, source copy `cardio:ctgov-nct01394952-2019-10-08`, retrieved 2026-10-26)
- Results first posted: 2019-10-08 (ClinicalTrials.gov record NCT01394952, source copy `cardio:ctgov-nct01394952-2019-10-08`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Chile; Colombia; Czechia; Germany; Hungary; Latvia; Lithuania; Mexico; New Zealand; Poland; Puerto Rico; Romania; Russia; South Africa; South Korea; Spain; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT01394952, source copy `cardio:ctgov-nct01394952-2019-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01394952-2019-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
- Acronym: REWIND
- Condition: Cardiovascular Disease
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial (`cardio:pubmed-31189509`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (`cardio:pubmed-31189511`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial (`cardio:pubmed-31924562`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial (`cardio:pubmed-32562683`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis (`cardio:pubmed-33239067`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial (`cardio:pubmed-33537745`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial (`cardio:pubmed-34153269`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND (`cardio:pubmed-34563178`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial (`cardio:pubmed-35043140`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis (`cardio:pubmed-36897834`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial (`cardio:pubmed-36723445`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis (`cardio:pubmed-41988866`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: db4ffc0d064cf1828b95940a9d60e45549479085df376e13fb0f09a95cb9ed68
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
